Australia markets closed

Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
213.20+0.90 (+0.42%)
At close: 05:29PM CEST
Full screen
Previous close212.30
Open213.90
Bid212.80 x 0
Ask213.10 x 0
Day's range209.50 - 214.90
52-week range139.55 - 245.40
Volume355,826
Avg. volume607,463
Market cap62.927B
Beta (5Y monthly)0.49
PE ratio (TTM)25.00
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Sobi publishes Q1 2022 report

    Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2022

  • PR Newswire

    Sobi publishes 2021 Annual and Sustainability Report

    Swedish Orphan Biovitrum AB (publ) (Sobi®) has released the company's 2021 Annual and Sustainability Report. The integrated report summarises business and strategy, financial performance and work on sustainability.

  • PR Newswire

    Sobi to cease ReFacto manufacturing in the first quarter of 2024

    Sobi® today announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF®/Xyntha® (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025. Manufacturing of drug substance for ReFacto will be transferred to Pfizer's production unit in Ireland, ensuring continued patient access.